TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic HCV infection at Screening.~2. Screening laboratory result indicating HCV genotype 1b infection.~3. Treatment-naïve and non-cirrhotic.~Exclusion Criteria:~1. HCV genotype or subtype other than GT1b.~2. Positive test result for Hepatitis B surface antigen (HbsAg) or confirmed positive anti-HIV antibody (HIV Ab) test.~3. Any current or past clinical evidence of cirrhosis.~4. Screening laboratory analyses that shows abnormal results.~5. Clinically significant abnormalities or co-morbidities, other than HCV infection that make the participant an unsuitable candidate for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (Type: EXPERIMENTAL): Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years old~* Signed informed consent~* Diagnosis of MDR/XDR-TB confirmed with standard microbiological criteria (culture-based, molecular or both)~* Treatment with linezolid 300mg twice daily per os.~Exclusion Criteria:~* Hypersensitivity to: linezolid, clarithromycin, erythromycin, or any macrolide antibiotics, or any of the excipients of linezolid or clarithromycin.~* Concomitant use with astemizole, cisapride, ergotamine derivatives (dihydroergotamine, ergotamine), monoamine oxidase inhibitors (phenelzine, isocarboxazid, selegiline, or moclobemide), pimozide, or terfenadine.~* Pregnancy or breast-feeding.~* Hypokalemia~* Concomitant use of other P-gp inhibitors/inducers, e.g. amiodarone, verapamil, digoxin, tipranavir/ritonavir, lovastatin, tariquidar, itraconazole, dipyridamol, erythromycin, ritonavir, quinidine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0mg, 250mg, and 500mg claritromycin (Type: OTHER): Patients receive 300mg linezolid twice a day during entire study. After one week, 250mg claritromycin once daily is added for a duration of two weeks.~After another two weeks, 250mg claritromycin is replaced by 500mg claritromycin once daily for another two weeks.~After this, there is a wash-out period of one week during which no claritromycine is administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1.Diagnosed with advanced non-small cell lung cancer 2.Patients with brain metastasis 3. Treated with ICIs~Exclusion Criteria:~* 1.Patients with a clear driver mutation that can be targeted for first-line treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy alone or chemotherapy combined with anti-angiogenesis (Type: None): patients with Chemotherapy
- immuntherapy (Type: None): patients treated with immune checkpoint inhibitor monotherapy or combination therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give written informed consent~* Age ≥ 18 years~* Male sex at birth~* Previously HIV-diagnosed OR HIV-seronegative at the time of last test within the past month and a current prescription for PrEP (both daily or event-driven permitted) or plan to start PrEP within 30 days after the enrollment visit~* Condomless anal or oral sexual contact with ≥ 1 male sex-at-birth partners in the past 12 months~* Diagnosed with GC, CT or early syphilis (primary, secondary or early latent) in the past 12 months. Note: self report of STI is acceptable if documentation not available. If the participant reports an incident STI in the past year at the same clinic where the participant will be enrolled, this diagnosis should be confirmed by chart review prior to enrollment. If the diagnosis from this clinic cannot be confirmed, the participant should not be enrolled. If the STI was reported at a clinical site that is not the study site, and records cannot be obtained, self-report will suffice.~Note: Syphilis diagnosis within the last year refers to primary syphilis, secondary syphilis, and documented early latent syphilis (\< 1 year since last syphilis diagnosis or negative test). Known late latent syphilis or latent syphilis of unknown duration would not qualify. Positive syphilis titers which represent serofast status and not active disease do not qualify as a syphilis diagnosis. Clinician judgement regarding qualifying syphilis diagnosis should be sought when the diagnosis of syphilis in the past year is not clear or if there is a question about serofast status vs. active infection.~Exclusion Criteria:~* Allergy to tetracycline class~* Current medications which may impact doxycycline metabolism or that are contraindicated with doxycycline, as per the prescribing information. These include systemic retinoids, barbiturates, carbamazepine, and phenytoin.~* Current use of warfarin, as intermittent doxycycling use can lead to an unpredictable impact on INR~* Anticipated use of doxycycline during the coming 12 months for non-STI prevention (e.g., acne treatment).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Doxy PEP (Type: EXPERIMENTAL): Doxycycline 200mg in addition to standard of care STI testing and treatment
- Control (Type: NO_INTERVENTION): The control arm will consist of standard of care STI testing and treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy man or woman~* Body mass index between 18 and 29.9 kg/m2~Exclusion Criteria:~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract~* Any surgery on the small intestine or colon, excluding appendectomy or cholecystectomy or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs~* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease, or any condition that may interfere with the subject successfully completing the trial or that would present a safety risk to the subject.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AZD1722 alone (Type: EXPERIMENTAL): 15 mg BID
- AD1722 with Renvela (Type: EXPERIMENTAL): AZD1722 15 mg BID and Renvela 800 mg TID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be at least 10 years of age~Exclusion Criteria:~* No active ocular disease

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5% (Type: EXPERIMENTAL): None
- Bepotastine Besilate Ophthalmic Solution 1.0% (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TLESR-impedance Study in Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written consent~* GERD patients, age 18-70 years, females must be postmenopausal or surgically sterilised~* 6 months history of GERD and incomplete response to PPI treatment~Exclusion Criteria:~* Insufficient symptom burden of the reflux disease evaluated by questionnaires~* S-creatinine \>1.2 times upper limit of normal~* History of heart disease~* Prior surgery of the upper GI tract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD3355
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~* Regular use of opioids for five years~* Injecting opioids in the past year~* Two attempts at treatment including one methadone (or other substitution)~* Must be a legal adult~* Struggling with drug related problems~General Exclusion Criteria:~* Pregnancy upon study entry~* Diagnosis of severe medical or psychiatric conditions contra-indicated for diacetylmorphine or hydromorphone treatment.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydromorphone (Type: EXPERIMENTAL): Phase I: Injectable Hydromorphone is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; or 2) switch to oral hydromorphone, for another six months.
- Diacetylmorphine (Type: ACTIVE_COMPARATOR): Phase I: Injectable Diacetylmorphine is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable Diacetylmorphine; or 2) switch to oral Diacetylmorphine, for another six months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Depakote ER in Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Bipolar I, II or NOS currently suffering from depression~* Both: both female and male participants are being studied~* Adults 18 years and older of any race~Exclusion Criteria:~* Schizophrenia or schizoaffective disorder and other disorders excluded at the discretion of the investigator's discretion~* Substance dependence within the past 3 months and abuse within the past 2 weeks prior to study.~* Positive screen for psychoactive drugs, stimulants or drugs of abuse (excluding marijuana, as long as dependence and abuse are ruled out according to DSM-IV)~* Significant risk harm to self or others based on history and mental status exam~* Clinically significant or unstable medical condition~* Unstable thyroid pathology and treatment initiated or altered within the past 3 months~* Clinically significant abnormal laboratory test results, vital signs, as judged by the investigators~* Women pregnant or nursing, or WOCBP who do not use adequate contraception or who are judged to be unreliable in their use of contraception~* Subjects who failed (because of inefficacy or adverse effects) an adequate trial of Depakote; eligible patient's may not have received Depakote within 30 days of screen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Depakote ER (Type: EXPERIMENTAL): Depakote ER up to 1500 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Are ambulatory.~* Have an established diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.~* Participants have a history of back pain ≥3 months with age at onset \<45 years.~* Have had prior treatment with at least 1 and not more than 2 TNF inhibitors.~* Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.~* Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.~Exclusion Criteria:~* Have total ankylosis of the spine.~* Have never taken a TNF inhibitor medication or have taken more than 2.~* Have recently received a live vaccine within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.~* Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis.~* Have a compromised immune system.~* Have any other serious and/or uncontrolled diseases.~* Have either a current diagnosis or a recent history of malignant disease.~* Have had major surgery within 8 weeks of baseline, or will require surgery during the study.~* Are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Q2W Ixekizumab (Type: EXPERIMENTAL): Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.
- Q4W Ixekizumab (Type: EXPERIMENTAL): Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.
- Placebo (Type: PLACEBO_COMPARATOR): Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject ≥ 15 years of age at the time of informed consent.~* Subject with Crohn's disease who received induction treatment of commercially available Humira® (160 mg initially and 80 mg at 2 weeks after initial dose), achieved response after initial dose, and then lost response during maintenance treatment with Humira®.~* Subject with elevated C-reactive Protein (CRP) at Screening.~* If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing an approved method of birth control throughout the study and for 150 days after the last dose of study drug.~* Subject has a negative tuberculosis (TB) screening assessment. If the subject has evidence of a latent TB infection; the subject must initiate and complete a minimum of 21 days of an ongoing TB prophylaxis (in such case, screening period can be prolonged until 21 days past after initiation of prophylaxis and study drug is administered) or have documented completion of a full course of TB prophylaxis, prior to Week 0.~Exclusion Criteria:~* Subject with suspicion of colitis other than Crohn's disease.~* Subject with an ostomy or ileoanal pouch. (Subjects with a previous ileo-rectal anastomosis are not excluded).~* Subject with abscess or suspicion of abscess, or subject with infection(s).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab 80 mg (Type: EXPERIMENTAL): All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testosterone Replacement Therapy in Chronic Spinal Cord Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males 18-49 years of age~* Chronic spinal cord injury~* Normal prostate specific antigen levels and digital rectal exam~* No known cardiovascular disease~* Subjects with total testosterone \> 4 ng/ml~* Subjects with total testosterone \> 4 ng/ml~Exclusion Criteria:~* Females~* Known coronary heart and/or artery disease, diabetes mellitus~* Previous or current cancer~* Current or previous anabolic steroid use~* Acute inter-current illness~* Abnormal liver function test (\>1.5 times normal values) at baseline~* Prostate specific antigen above normal~* Abnormal digital rectal exam at baseline suggestive of malignancy~* Current alcohol or drug abuse~* Significant psychological disorders

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Testosterone Replacement Therapy (Type: EXPERIMENTAL): Subjects with Low Testosterone (Hypogonadal) Receive Testosterone Transdermal System (Androderm 5 mg patch)
- No Intervention (Type: NO_INTERVENTION): Subjects with normal testosterone levels (eugonadal) participated in identical outcome measurements at parallel time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with refractory or recurrent Plantar Warts.~* No wart treatment for the last 12 weeks~* Healthy male or non-pregnant, non-lactating female aged ≥ 18 years or greater~* If female of childbearing potential, use an acceptable form of birth control during the study~* Provide written informed consent or (HIPAA consent/authorization, as applicable~Exclusion Criteria:~* Concurrent medical disorder or disease making implementation or interpretation of the protocol or results difficult or unsafe~* Female subjects who are breast-feeding or planning to become pregnant~* Patients with a history of allergy to silver or fruits~* Subjects with clinically significant unstable medical disorder, life threatening disease, or current malignancies~* Subjects with History of Alcohol abuse or other drug abuse within 2 years prior to Randomization~* Subjects who have been treated with an investigational drug or investigational device within a period of 30 days prior to study enrollment~* Concomitant Medications: any other wart therapy is prohibited during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Nowarta110 3 drops (Type: EXPERIMENTAL): Nowarta110 3 drops administration
- Nowarta110 6 drops (Type: EXPERIMENTAL): Nowarta110 6 drops administration
- Nowarta110 10 drops (Type: EXPERIMENTAL): Nowarta110 10 drops administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete